SG11201901534VA - Combination therapy with controlled-release cnp agonists - Google Patents
Combination therapy with controlled-release cnp agonistsInfo
- Publication number
- SG11201901534VA SG11201901534VA SG11201901534VA SG11201901534VA SG11201901534VA SG 11201901534V A SG11201901534V A SG 11201901534VA SG 11201901534V A SG11201901534V A SG 11201901534VA SG 11201901534V A SG11201901534V A SG 11201901534VA SG 11201901534V A SG11201901534V A SG 11201901534VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- disorders
- controlled
- stimulating growth
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 5
- 238000013270 controlled release Methods 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000004936 stimulating effect Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 208000037824 growth disorder Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16191456 | 2016-09-29 | ||
| PCT/EP2017/074596 WO2018060314A1 (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901534VA true SG11201901534VA (en) | 2019-03-28 |
Family
ID=57047055
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901534VA SG11201901534VA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
| SG10202111952PA SG10202111952PA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202111952PA SG10202111952PA (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US11564974B2 (lt) |
| EP (2) | EP3518930B1 (lt) |
| JP (1) | JP7189133B2 (lt) |
| KR (2) | KR102531327B1 (lt) |
| CN (1) | CN109843295B (lt) |
| AU (2) | AU2017336253B2 (lt) |
| BR (1) | BR112019005351A2 (lt) |
| CA (1) | CA3037448A1 (lt) |
| DK (1) | DK3518930T3 (lt) |
| ES (1) | ES2943013T3 (lt) |
| FI (1) | FI3518930T3 (lt) |
| HR (1) | HRP20230385T1 (lt) |
| HU (1) | HUE062117T2 (lt) |
| IL (3) | IL305975A (lt) |
| LT (1) | LT3518930T (lt) |
| MA (1) | MA46430B1 (lt) |
| MX (1) | MX2019003173A (lt) |
| NZ (1) | NZ751746A (lt) |
| PL (1) | PL3518930T3 (lt) |
| PT (1) | PT3518930T (lt) |
| RS (1) | RS64203B1 (lt) |
| RU (1) | RU2768747C2 (lt) |
| SG (2) | SG11201901534VA (lt) |
| SI (1) | SI3518930T1 (lt) |
| WO (1) | WO2018060314A1 (lt) |
| ZA (1) | ZA201901810B (lt) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| EP3400019B1 (en) | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| CN115177720A (zh) | 2016-01-08 | 2022-10-14 | 阿森迪斯药物生长障碍股份有限公司 | 具有低npr-c结合的控制释放cnp激动剂 |
| CA3007976C (en) * | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| EP3400065A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| KR102331820B1 (ko) | 2016-03-01 | 2021-11-29 | 아센디스 파마 본 디지즈 에이/에스 | Pth 프로드럭 |
| SG11201901576QA (en) | 2016-09-29 | 2019-03-28 | Ascendis Pharma Bone Diseases As | Dosage regimen for a controlled-release pth compound |
| KR102531327B1 (ko) | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
| KR102611820B1 (ko) | 2016-09-29 | 2023-12-07 | 아센디스 파마 본 디지즈 에이/에스 | 낮은 피크 대 트로프 비를 가진 pth 화합물 |
| WO2024104922A1 (en) | 2022-11-14 | 2024-05-23 | Ascendis Pharma Growth Disorders A/S | Method of improving skeletal muscle function |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI0892789T2 (sl) | 1996-04-12 | 2010-03-31 | Warner Lambert Co | Ireverzibilni inhibitorji tirozin kinaz |
| US6329375B1 (en) | 1997-08-05 | 2001-12-11 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
| US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
| CN1169573C (zh) | 1998-09-28 | 2004-10-06 | 参天制药株式会社 | 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂 |
| BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
| JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
| SG159381A1 (en) | 2001-10-10 | 2010-03-30 | Novo Nordisk As | Remodeling and glycoconjugation of peptides |
| US7054679B2 (en) | 2001-10-31 | 2006-05-30 | Robert Hirsh | Non-invasive method and device to monitor cardiac parameters |
| US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
| CN100558398C (zh) | 2002-11-26 | 2009-11-11 | 拜奥康有限公司 | 修饰的钠尿化合物、缀合物及其应用 |
| US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
| SI1620118T1 (sl) | 2003-04-08 | 2014-11-28 | Yeda Research And Development Co., Ltd. | Reverzibilna pegilirana zdravila |
| US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
| CA2539253A1 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| ES2741524T3 (es) | 2004-03-23 | 2020-02-11 | Ascendis Pharma Gmbh | Profármaco polimérico con un enlazador autoinmolador |
| US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
| GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
| CU23556A1 (es) | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| MX2009002504A (es) | 2006-09-08 | 2009-05-22 | Mayo Foundation | Polipeptidos acuareticos y natriureticos que carecen de actividad vasodilatadora. |
| EP2063709A2 (en) | 2006-09-15 | 2009-06-03 | Enzon Pharmaceuticals, Inc. | Hindered ester-based biodegradable linkers for oligonucleotide delivery |
| CA2668814A1 (en) | 2006-11-09 | 2008-06-05 | Alcon Research, Ltd. | Water insoluble polymer matrix for drug delivery |
| KR20080098216A (ko) | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| DK2173890T3 (da) | 2007-06-21 | 2011-06-27 | Univ Muenchen Tech | Biologisk aktive proteiner med forhøjet stabilitet in vivo og/eller in vitro |
| TW200922624A (en) | 2007-07-11 | 2009-06-01 | Enzon Pharmaceuticals Inc | Polymeric drug delivery system containing a multi-substituted aromatic moiety |
| JP2011504506A (ja) * | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｃ型ナトリウム利尿ペプチドの変異体 |
| CN101980725B (zh) | 2008-02-01 | 2013-06-12 | 阿森迪斯药物股份有限公司 | 包含可自裂解的连接体的前药 |
| WO2009143412A2 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
| WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| EP2334335A1 (en) | 2008-09-19 | 2011-06-22 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
| ES2610356T3 (es) | 2009-02-03 | 2017-04-27 | Amunix Operating Inc. | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
| HRP20220057T1 (hr) | 2009-05-20 | 2022-04-15 | Biomarin Pharmaceutical Inc. | Varijante natriuretičnog peptida c-tipa |
| NZ597960A (en) | 2009-07-31 | 2013-07-26 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
| EP2459227B1 (en) | 2009-07-31 | 2021-03-17 | Ascendis Pharma A/S | Prodrugs containing an aromatic amine connected by an amide bond to a carrier |
| WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
| WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
| US20120289571A1 (en) | 2009-12-31 | 2012-11-15 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
| WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
| WO2011089215A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
| WO2011089214A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Carrier-linked carbamate prodrug linkers |
| WO2011123813A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same |
| US8754190B2 (en) | 2010-05-05 | 2014-06-17 | Prolynx Llc | Controlled release from macromolecular conjugates |
| CN103025164B (zh) | 2010-05-05 | 2017-03-08 | 普罗林科斯有限责任公司 | 从固体支撑物中药物的控制释放 |
| WO2011144756A1 (en) | 2010-05-21 | 2011-11-24 | Xl-Protein Gmbh | Biosynthetic proline/alanine random coil polypeptides and their uses |
| CN102959585B (zh) | 2010-06-30 | 2016-03-30 | 日本电气方案创新株式会社 | 属性确定方法、属性确定装置及属性确定系统 |
| WO2013024053A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
| JP6092867B2 (ja) | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー／エス | 担体連結しているトレプロスチニルプロドラッグ |
| WO2013024048A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
| US20140323402A1 (en) | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
| CA2843875C (en) | 2011-08-12 | 2020-01-07 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
| WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| CA2871579A1 (en) | 2012-04-25 | 2013-10-31 | Daiichi Sankyo Company, Limited | Use of a c-type natriuretic peptide as a bone repair promoter |
| AU2013254756B2 (en) | 2012-04-25 | 2017-03-30 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US9855340B2 (en) | 2012-10-11 | 2018-01-02 | Ascendis Pharma A/S | Hydrogel prodrugs |
| EP2908845A1 (en) | 2012-10-17 | 2015-08-26 | Novo Nordisk Health Care AG | Fatty acid acylated amino acids for growth hormone delivery |
| JP6536871B2 (ja) * | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Ｆｇｆｒ３病の予防および治療剤ならびにそのスクリーニング方法 |
| JPWO2015129812A1 (ja) | 2014-02-27 | 2017-03-30 | 第一三共株式会社 | ステロイド剤投与で誘発される成長障害に対する医薬 |
| IL307773A (en) | 2014-11-18 | 2023-12-01 | Ascendis Pharma Endocrinology Div A/S | Novel polymeric human growth hormone drug matrices |
| WO2016110577A1 (en) | 2015-01-09 | 2016-07-14 | Ascendis Pharma A/S | Cnp prodrugs |
| US11202819B2 (en) | 2015-12-08 | 2021-12-21 | Biomarin Pharmaceutical Inc. | Use of C-type natriuretic peptide variants to treat osteoarthritis |
| EP3400018A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| AU2017205693B2 (en) | 2016-01-08 | 2022-03-31 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with low initial NPR-B activity |
| EP3400065A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| CA3007976C (en) | 2016-01-08 | 2023-09-26 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| CN115177720A (zh) | 2016-01-08 | 2022-10-14 | 阿森迪斯药物生长障碍股份有限公司 | 具有低npr-c结合的控制释放cnp激动剂 |
| EP3400019B1 (en) | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with carrier attachment at the ring moiety |
| KR102331820B1 (ko) | 2016-03-01 | 2021-11-29 | 아센디스 파마 본 디지즈 에이/에스 | Pth 프로드럭 |
| KR102531327B1 (ko) | 2016-09-29 | 2023-05-11 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 조절 방출 cnp 아고니스트를 사용한 병용 요법 |
| KR20210047309A (ko) | 2018-08-16 | 2021-04-29 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 면역 반응을 자극하기 위한 방법 및 조성물 |
| MX2021008708A (es) | 2019-02-11 | 2021-09-21 | Ascendis Pharma Growth Disorders As | Formulaciones farmaceuticas secas de conjugados de peptido natriuretico tipo c (cnp). |
-
2017
- 2017-09-28 KR KR1020197012470A patent/KR102531327B1/ko active IP Right Grant
- 2017-09-28 IL IL305975A patent/IL305975A/en unknown
- 2017-09-28 IL IL290054A patent/IL290054B2/en unknown
- 2017-09-28 BR BR112019005351A patent/BR112019005351A2/pt unknown
- 2017-09-28 HR HRP20230385TT patent/HRP20230385T1/hr unknown
- 2017-09-28 FI FIEP17781429.0T patent/FI3518930T3/fi active
- 2017-09-28 RS RS20230385A patent/RS64203B1/sr unknown
- 2017-09-28 EP EP17781429.0A patent/EP3518930B1/en active Active
- 2017-09-28 KR KR1020237015410A patent/KR20230066147A/ko not_active Application Discontinuation
- 2017-09-28 JP JP2019516647A patent/JP7189133B2/ja active Active
- 2017-09-28 PT PT177814290T patent/PT3518930T/pt unknown
- 2017-09-28 DK DK17781429.0T patent/DK3518930T3/da active
- 2017-09-28 RU RU2019112897A patent/RU2768747C2/ru active
- 2017-09-28 LT LTEPPCT/EP2017/074596T patent/LT3518930T/lt unknown
- 2017-09-28 MA MA46430A patent/MA46430B1/fr unknown
- 2017-09-28 MX MX2019003173A patent/MX2019003173A/es unknown
- 2017-09-28 US US16/338,185 patent/US11564974B2/en active Active
- 2017-09-28 PL PL17781429.0T patent/PL3518930T3/pl unknown
- 2017-09-28 SG SG11201901534VA patent/SG11201901534VA/en unknown
- 2017-09-28 HU HUE17781429A patent/HUE062117T2/hu unknown
- 2017-09-28 CA CA3037448A patent/CA3037448A1/en active Pending
- 2017-09-28 SI SI201731339T patent/SI3518930T1/sl unknown
- 2017-09-28 NZ NZ751746A patent/NZ751746A/en unknown
- 2017-09-28 EP EP23159718.8A patent/EP4223309A1/en active Pending
- 2017-09-28 AU AU2017336253A patent/AU2017336253B2/en active Active
- 2017-09-28 WO PCT/EP2017/074596 patent/WO2018060314A1/en unknown
- 2017-09-28 CN CN201780058524.8A patent/CN109843295B/zh active Active
- 2017-09-28 ES ES17781429T patent/ES2943013T3/es active Active
- 2017-09-28 SG SG10202111952PA patent/SG10202111952PA/en unknown
-
2019
- 2019-03-25 IL IL265592A patent/IL265592B/en unknown
- 2019-03-25 ZA ZA2019/01810A patent/ZA201901810B/en unknown
-
2022
- 2022-12-22 US US18/145,676 patent/US20230302091A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201709A patent/AU2023201709A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201906431UA (en) | Method for the treatment of thromboembolism | |
| SG11201811432WA (en) | Rna for cancer therapy | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201808270PA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901576QA (en) | Dosage regimen for a controlled-release pth compound | |
| SG11201805311XA (en) | Method of treating a mammal, including human, against cancer using methionine and asparagine depletion | |
| SG11201906543RA (en) | HDAC INHIBITORS-BASED ANTIBODY DRUG CONJUGATES (ADCs) AND USE IN THERAPY | |
| SG11201805195YA (en) | Composition comprising botulinum toxin | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201805755SA (en) | Methods of administering hepcidin | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11201810940XA (en) | Methods of treating pancreatic cancer | |
| SG11201900214UA (en) | Iso-citrate dehydrogenase (idh) inhibitor | |
| SG11201907505TA (en) | Low-viscosity, high-concentration evolocumab formulations and methods of making the same |